Jonvir-ET Tablet

Jonvir-ET Tablet is a combination of antiretrovirals medicines. It is prescribed to treat HIV (human immunodeficiency virus) infection. It boosts up the immunity to fight against HIV to manage or treat AIDS (acquired immunodeficiency syndrome).

Jonvir-ET Tablet restricts the growth of HIV in the body and reduces the risk of getting HIV-related complications to improve the lifespan of an individual. The medicine should be taken in an empty stomach, preferably at bedtime for better efficacy. Taking these medicines regularly at the same time increases their effectiveness. A dose of this medicine must not be missed as it can affect your recovery. It is important to complete the full course of the treatment until your doctor advises you to stop it.

The most common side effects of this medicine are impaired concentration, abnormal dreams, headache, nausea, weakness and fatigue, nasal congestion, diarrhea, rash, dizziness, trouble sleeping, pain, depression, and cough. These are usually not serious and go away within 2-4 weeks of treatment, however, inform your doctor if they bother you or do not go away. As it can also make you feel dizzy or drowsy, it is advised to avoid driving. In addition to that, avoid alcohol consumption as it may increase the intensity of the side effects.

Before starting with the treatment, you should consult your doctor if you are pregnant or breastfeeding, or have any kidney, liver, or other diseases. Your doctor may suggest some laboratory tests before and during the treatment to check your blood counts, liver and kidney functioning, and other health and mental conditions. If you are HIV positive, you should not breastfeed or share personal belongings like razors or toothbrushes. Consult your doctor to know about safe sex methods to prevent transmission of HIV during intercourse.

• Treatment of HIV infection

Treatment of HIV infection
Jonvir-ET Tablet prevents HIV from multiplying in the body. It helps control the infection and make the immune system work better. This lowers the chances of getting complications, such as new infections, and improves the quality of life.

It is not a cure of HIV or AIDS and should not be used to prevent HIV after accidental exposure to a risk. It is important to take this medicine as prescribed by the doctor. Taking all doses in the right amount at the right times greatly increases the effectiveness of this combination of medicines and reduces the chances of HIV infection becoming resistant to antiretroviral medicines. Although taking this medicine does not prevent the passing of HIV to other people.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Lacavir-ET

• Headache
• Dizziness
• Nausea
• Insomnia (difficulty in sleeping)
• Weakness
• Depression
• Diarrhea
• Rash
• Pain
• Fever
• Decreased white blood cell count (neutrophils)
• Peripheral neuropathy (tingling and numbness of feet and hand)
• Back pain
• Abdominal pain
• Anxiety
• Vomiting
• Joint pain
• Pneumonia
• Dyspepsia
• Muscle pain
• Lipodystrophy (skin thickening or pits at the injection site)
• Hypercholesterolemia (high cholesterol)
• Increased triglyceride level in blood
• Elevated creatinine kinase
• Elevated levels of serum amylase
• Blood in urine
• Increased transaminase level in blood

Severe side effects of Lacavir-ET

• Anemia (low number of red blood cells)
• Muscle damage
• Hypersensitivity reaction
• Impaired coordination
• Abnormality of voluntary movements
• Convulsion
• Tremors
• Breast enlargement in male
• Pancreatic inflammation
• Liver failure
• Hepatitis (viral infection of liver)
• Lactic acidosis
• Fatty liver disease
• Worsening of hepatitis B (viral infection of liver)
• Breathlessness
• Erythema multiforme
• Stevens-Johnson syndrome
• Increased glucose level in blood
• Rhabdomyolysis
• Softening of bones
• Decreased potassium level in blood
• Muscle weakness
• Decreased phosphate level in blood
• Immune reconstitution syndrome

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Jonvir-ET Tablet is to be taken empty stomach.

Jonvir-ET Tablet is a combination of three antiviral medicines: Lamivudine, Tenofovir disoproxil fumarate and Efavirenz. They work by preventing HIV (virus) from multiplying, thereby reducing the amount of virus in your body. They also increase the CD4 cell (white blood cells that protect against infection) count in your blood.

• Jonvir-ET Tablet is a combination of three medicines which slows down or stops the progression of HIV infections.
• Take it on an empty stomach, preferably at bedtime, to reduce side effects.
• Skipping doses increases the risk of treatment failure. Make sure that you take all your doses at the correct time.
• Jonvir-ET Tablet may cause dizziness or sleepiness. Don't drive or do anything requiring concentration until you know how it affects you.
• Jonvir-ET Tablet can cause birth defects. Use effective contraception while taking Jonvir-ET Tablet and 12 weeks after stopping it.
• It may cause weakening of your bones. Exercise regularly and take calcium and vitamin D supplements as suggested by your doctor.
• Your doctor may monitor your kidney and liver functions regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, darkened urine or yellowing of the eyes or skin.
• Do not stop taking Jonvir-ET Tablet without your doctor’s advice.

Tenofovir Disoproxil Fumarate+Lamivudine+Efavirenz. Place of publication: Mylan Laboratories Limited; Sep. 2014. [Accessed 09 Apr. 2019] (online) Available from:

Lamivudine. South Ruislip, Middlesex: Aurobindo Pharma - Milpharm Ltd.; 2012 [revised 24 Jun. 2018]. [Accessed 09 Apr. 2019] (online) Available from:

Tenofovir disoproxil. Limassol, Cyprus: Remedica Ltd.; 2018. [Accessed 09 Apr. 2019] (online) Available from:

Efavirenz. South Ruislip, Middlesex: Aurobindo Pharma - Milpharm Ltd.; 2014 [revised 10 Dec. 2018]. [Accessed 09 Apr. 2019. 2019] (online) Available from: